Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Contemp Clin Trials. 2022 Aug 24;120:106895. doi: 10.1016/j.cct.2022.106895

Table 2.

Baseline Characteristics.

Characteristic Intervention (N = 150) Usual Care (N = 150)
Age – year median (iqr) 71 (64–78) 73 (65–79)
Female sex - NO (%) 2 (0.01%) 2 (0.01%)
Race - NO (%)
 Black or african american 49 (38%) 43 (33%)
 White 74 (57%) 82 (63%)
 Asian 5 (4%) 2 (1%)
 Native hawaiian or other pacific islander 2 (2%) 2 (2%)
 American indian or alaska native usual care 0 (0%) 1 (1%)
3 month (3 M) hospitalization rank* 92 (83–97) 91 (81–97)
>1 HF admissions (VA-1Y) (%)** 4.7% 4.7%
Optimization potential score - NO (%)
 0 19 (13%) 18 (12%)
 1 22 (15%) 24 (16%)
 2 38 (25%) 36 (24%)
 3 31 (21%) 32 (21%)
 4 22 (15%) 21 (14%)
 5 18 (12%) 19 (13%)
GDMT prescribed – No (%)
 ACE/ARB/ARNI 102 (68%) 99 (66%)
 Beta blocker 118 (79%) 120 (80%)
 MRA 44 (29%) 44 (29%)
 SGLT-2i 16 (11%) 17 (11%)
GDMT target dose achieved – NO (%)
 ACE/ARB/ARNI 15 (10%) 15 (10%)
 BETA BLOCKER 15 (10%) 18 (12%)
 MRA 16 (11%) 14 (9%)
 SGLT-2i 16 (11%) 17 (11%)
Systolic blood pressure (mm Hg, 1Y) 125 (111–134) 119 (107–135)
Diastolic blood pressure (mm Hg, 1Y) 69 (59–77) 69 (58–79)
Pulse (beats per minute, 1Y) 75 (66–85) 74 (67–85)
Weight (pounds, 3Y) 187 (158–222) 188 (157–225)